Showing 1861-1870 of 2657 results for "".
- EMA Review Finds Rare Risk of Vision Loss Associated With Semaglutide Medicineshttps://modernod.com/news/ema-review-finds-rare-risk-of-vision-loss-associated-with-semaglutide-medicines/2482842/The European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded its review of semaglutide-containing medicines following concerns about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAIO
- Pangaea Data Secures Investment from Topcon Healthcare to Scale AI Platformhttps://modernod.com/news/pangaea-data-secures-investment-from-topcon-healthcare-to-scale-ai-platform/2482821/Pangaea Data announced an investment from Topcon Healthcare to accelerate the application of Pangaea’s AI platform, which aims to address care gaps in eye health and systemic disease. Financial terms of the deal were not disclosed.
- Eylea 8 mg Approved in China for Wet AMDhttps://modernod.com/news/eylea-8-mg-approved-in-china-for-wet-amd/2482817/The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of wet age-related macular degeneration (AMD) in China. The approval is based on positive results from the phase 3 PULSAR trial a
- Allotex Files IDE with FDA for Collagen-Based Corneal Implanthttps://modernod.com/news/allotex-files-ide-with-fda-for-collagen-based-corneal-implant/2482813/Allotex announced the submission of its investigational device exemption (IDE) to the FDA, marking a step toward US clinical trials of the company’s human collagen-based corneal implant, Allo-1. Allo-1 offers a novel approach to near vision enhancement through biolo
- Grifols Receives FDA Clearance to Initiate Phase 2 Trial of Immunoglobulin Drops for Dry Eye Diseasehttps://modernod.com/news/grifols-receives-fda-clearance-of-ind-application-for-phase-2-trial-of-immunoglobulin-drops-for-dry-eye-disease/2482812/Grifols, a producer of plasma-derived medicines, announced that the FDA has cleared the company’s investigational new drug (IND) application to initiate a phase 2 trial evaluating its immunoglobulin (IG) drops–GRF312 ophthalmic solution–fo
- Hoya Vision Care Presents New Data on Myopia Management Spectacle Lenses at ARVOhttps://modernod.com/news/hoya-vision-care-presents-new-data-on-myopia-management-spectacle-lenses-at-arvo/2482800/Hoya Vision Care announced new clinical evidence from three key clinical studies highlighting the impact of 'Defocus Incorporated Multiple Segments (DIMS)' technology. The results were presented as part of the company’s 2025 scientific program, 'Exploring New Frontiers in Myopia
- Genentech: Largest Real-World Studies Show Vabysmo’s Long-Term Benefits for Wet AMD, DMEhttps://modernod.com/news/genentech-largest-real-world-studies-show-vabysmos-long-term-benefits-for-wet-amd-dme/2482798/Genentech presented more than 20 abstracts across its ophthalmology portfolio at the 2025 Association for Research in Vision and Ophthalmology (ARVO) annual meeting. Key studies highlight Vabysmo’s long-term ability to sustain vision improvements in patients with wet
- Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Resultshttps://modernod.com/news/isarna-therapeutics-presents-positive-phase-2-better-trial-final-results-at-arvo-2025/2482797/Isarna Therapeutics presented final positive results from its phase 2 BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on May 6. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, shared data
- Topcon Healthcare Acquires RetInSight to Accelerate AI-Powered Imaging in Eye Carehttps://modernod.com/news/topcon-healthcare-acquires-retinsight-to-accelerate-ai-powered-imaging-in-eye-care/2482777/Topcon Healthcare announced the acquisition of Vienna, Austria-based RetInSight. The move advances Topcon Healthcare’s vision of Healthcare from the Eye, enhancing access to intelligent diagnostics that increase access to high-quality eye care, reduce healthcare costs, and improve
- Nanoscope to Present New Data for Optogenetic Therapy for RP at Eyecelerator and ARVOhttps://modernod.com/news/nanoscope-to-present-new-data-for-optogenetic-therapy-for-rp-at-eyecelerator-and-arvo/2482769/Nanoscope Therapeutics announced participation at both the Eyecelerator and The Association for Research and Vision in Ophthalmology (ARVO) 2025 annual meetings. Nanoscope’s presentations will be centered around 126-week outcomes following treatment with its MCO-010